Pancreatic Cancer Research

ResearcherTongji HospitalActive in the last 2 years

Xiuhui Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5327-8247; OpenAlex author ID A5051700425. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2018: 6 papers · 2019: 2 papers · 2020: none · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: 1 paper

Papers 16

  1. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Co-author DOI 10.1016/j.ccell.2024.03.009↗
  2. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  3. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-β Signaling Axis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.02.017↗
  4. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2022.06.058↗
  5. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103271↗
  6. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.12.077↗
  7. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  8. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… Co-author DOI 10.7150/ijbs.49514↗
  9. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Co-author DOI 10.1038/s41419-019-2123-y↗
  10. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. Co-author DOI 10.1186/s13046-019-1343-4↗
  11. Loss of Linc01060 induces pancreatic cancer progression through vinculin-mediated focal adhesion turnover. Co-author DOI 10.1016/j.canlet.2018.06.015↗
  12. Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. First author DOI 10.1016/j.taap.2018.08.003↗
  13. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Co-author DOI 10.1038/s41598-018-22493-5↗
  14. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. Co-author DOI 10.1186/s12885-018-4948-7↗
  15. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Co-author DOI 10.18632/oncotarget.22976↗
  16. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.24443↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhijun Zhou · 7 shared papers, 2021–2024 · strength 0.90
  2. Jingxuan Yang · 7 shared papers, 2021–2024 · strength 0.90
  3. Renyi Qin · 9 shared papers, 2018–2022 · strength 0.83
  4. Ruizhi He · 9 shared papers, 2018–2022 · strength 0.80
  5. Min Li · 6 shared papers, 2021–2024 · strength 0.80
  6. Mingyang Liu · 6 shared papers, 2021–2024 · strength 0.80
  7. Min Wang · 8 shared papers, 2018–2022 · strength 0.75
  8. Shutao Pan · 8 shared papers, 2018–2022 · strength 0.71
  9. Xingjun Guo · 8 shared papers, 2018–2022 · strength 0.70
  10. Courtney W. Houchen · 5 shared papers, 2021–2024 · strength 0.68
  11. Chunle Zhao · 6 shared papers, 2018–2022 · strength 0.56
  12. Yan Zhao · 6 shared papers, 2018–2022 · strength 0.50
  13. Min Zhou · 4 shared papers, 2018–2022 · strength 0.41
  14. Min Zhou · 5 shared papers, 2018–2019 · strength 0.40
  15. Xu Li · 4 shared papers, 2018–2022 · strength 0.37
  16. Yuhui Liu · 3 shared papers, 2019–2022 · strength 0.32
  17. Hanxiang Zhan · 2 shared papers, 2021 · strength 0.22
  18. Taoyuan Yin · 2 shared papers, 2019–2022 · strength 0.22
  19. Li Xu · 2 shared papers, 2019–2021 · strength 0.20
  20. Alex Arreola · 1 shared paper, 2024 · strength 0.17
  21. Lei Zheng · 1 shared paper, 2024 · strength 0.17
  22. Ryan David Nipp · 1 shared paper, 2024 · strength 0.17
  23. Hua Chen · 2 shared papers, 2018–2019 · strength 0.17
  24. Yuqing Zhang · 1 shared paper, 2022 · strength 0.12
  25. Chengjian Shi · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.